Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

Inclusion Criteria: * Patients aged at least 18 years * Patients with secondary hyperparathyroidism associated with CKD stage 5, serum iPTH \> 150 pg/mL, * Cardiac disease as described by Medical Dictionary for Regulatory Activities (MedDRA) terms: * cardiac disorder as cardiac arrhythmias * cardiac disorder signs and symptoms * cardiac neoplasm * cardiac valve disorder * heart failures * myocardial disorder * pericardial disorder * Serum phosphate level \< 6.5 mg/dL and serum calcium level \< 10.5 mg/dL Exclusion Criteria: * Patients who meet contraindications as outlined in the latest version of Zemplar (Paricalcitol IV) summary of product characteristics * Patients with known hypersensitivity to paricalcitol or any component of the formulation, vitamin D intoxication, hypercalcemia; cinacalcet as concomitant medication.